跳转至内容
Merck
CN
  • Chronic deep brain stimulation of the medial forebrain bundle reverses depressive-like behavior in a hemiparkinsonian rodent model.

Chronic deep brain stimulation of the medial forebrain bundle reverses depressive-like behavior in a hemiparkinsonian rodent model.

Experimental brain research (2015-07-22)
Luciano L Furlanetti, Volker A Coenen, Iñigo A Aranda, Máté D Döbrössy
摘要

Preclinical and clinical evidence suggests that depression might be associated with a dysfunction in the reward/motivation circuitry. Deep brain stimulation (DBS) of the superolateral branch of the medial forebrain bundle (MFB) has been shown in a recent clinical trial to provide a prompt and consistent improvement of depressive symptoms in treatment-resistant patients. In order to better understand the underlying mechanisms of neuromodulation in the context of depression, the effects of chronic bilateral MFB-DBS were assessed in a combined rodent model of depression and Parkinson's disease. Female Sprague-Dawley rats received unilateral 6-OHDA injection in the right MFB and were divided into three groups: CMS-STIM, CMS-noSTIM and control group. The CMS groups were submitted to chronic unpredictable mild stress (CMS) protocol for 6 weeks. MFB-DBS was applied only to the CMS-STIM group for 1 week. All groups were repeatedly probed on a series of behavioral tasks following each intervention, and to a postmortem histological analysis. CMS led to an increase in immobility in the forced swim test, to a decrease in sucrose solution consumption in the sucrose preference test, as well as to an increased production of ultrasonic vocalizations in the 22 kHz range, indicating increased negative affect. MFB-DBS reversed the anhedonic-like and despair-like behaviors. The results suggest that unilateral dopamine depletion did not preclude MFB-DBS in reversing depressive-like and anhedonic-like behavior in the rodent. Further understanding of the importance of hemispheric dominance in neuropsychiatric disorders is essential in order to optimize stimulation as a therapeutic strategy in these diseases.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
硼氢化钠, powder, ≥98.0%
Sigma-Aldrich
L -抗坏血酸, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L -抗坏血酸, BioXtra, ≥99.0%, crystalline
Sigma-Aldrich
L -抗坏血酸, suitable for cell culture, suitable for plant cell culture, ≥98%
Sigma-Aldrich
L -抗坏血酸, 99%
Sigma-Aldrich
L -抗坏血酸, reagent grade, crystalline
Sigma-Aldrich
磷酸钠, 96%
Sigma-Aldrich
过氧化氢 溶液, contains ~200 ppm acetanilide as stabilizer, 3 wt. % in H2O
Sigma-Aldrich
6-羟基多巴胺 盐酸盐, ≥97% (titration), powder
Sigma-Aldrich
L -抗坏血酸, ACS reagent, ≥99%
Supelco
L -抗坏血酸, analytical standard
Sigma-Aldrich
过氧化氢 溶液, contains inhibitor, 35 wt. % in H2O
Sigma-Aldrich
L -抗坏血酸, meets USP testing specifications
Sigma-Aldrich
L -抗坏血酸, reagent grade
Sigma-Aldrich
过氧化氢 溶液, 34.5-36.5%
Sigma-Aldrich
抗-血清素 兔抗, whole antiserum
Sigma-Aldrich
L -抗坏血酸, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Sigma-Aldrich
L -抗坏血酸, FCC, FG
Sigma-Aldrich
L -抗坏血酸, BioUltra, ≥99.5% (RT)
Sigma-Aldrich
L -抗坏血酸, puriss. p.a., ≥99.0% (RT)
Sigma-Aldrich
硼氢化钠 溶液, 2.0 M in triethylene glycol dimethyl ether
Sigma-Aldrich
DL-酪氨酸, 99%
Sigma-Aldrich
L -抗坏血酸, Vetec, reagent grade, 99%